“Bimekizumab Response Maintenance to 48 Weeks in Patients With Moderate to Severe Hidradenitis Suppurativa: Pooled Responder Analysis from the Phase 3, Double-Blind, Placebo-Controlled, Randomized Clinical Trials BE HEARD I and II”. 2024. SKIN The Journal of Cutaneous Medicine 8 (2): s396. https://doi.org/10.25251/skin.8.supp.396.